• Home
  • Sitemap
  • Help
  • Technical Support
  • Contact
Inflammation
You are here: Product Lines > Inflammation
Toolbar - View Selection
 
 Items 180-200 of 673 Page 10 of 34 Select Page: << 1 2 3 4 5 6 7 8 9 10  >>  
ALX-300-097 Revised 09-Dec-04
1,2-Dimyristoyl-sn-glycero-3-phosphomethanol . sodium salt
Add to Clipboard
PRODUCT LINE Signal Transduction
PRODUCT CATEGORY Phospholipids / Related Products
Ordering Information
Product Numbers: Format: Size: Unit Price: Quantity: Add To Cart
ALX-300-097-M050   50 mg 30.00 USD Add To Cart
ALX-300-097-M250   250 mg 90.00 USD Add To Cart
Product Specification
FORMULA: C32H62O8P . Na
MW: 605.8 . 23.0
PURITY: ≥99%
APPEARANCE: Off-white solid.
SHIPPING: AMBIENT
LONG TERM STORAGE: -20°C

Product Description
Substrate for kinetic studies of phospholipase A2.
Product Specific Literature References
Kinetics of interfacial catalysis by phospholipase A2 in intravesicle scooting mode, and heterofusion of anionic and zwitterionic vesicles: M.K. Jain, et al.; Biochim. Biophys. Acta 860, 435 (1986) Abstract
Competitive inhibition of phospholipase A2 in vesicles: M.K. Jain, et al.; Biochemistry 28, 4135 (1989) Abstract
Active-site-directed specific competitive inhibitors of phospholipase A2: novel transition-state analogues: M.K. Jain, et al.; Biochemistry 30, 10256 (1991) Abstract
Further Categories Containing This Product:
PLA2 Substrates
 
 
ALX-385-031 Revised 07-Oct-08
Diosmin
Add to Clipboard
SYNONYMS 3’,5,7-Trihydroxy-4’-methoxyflavone 7-rutinoside
PRODUCT LINE Natural Products / Antibiotics
PRODUCT CATEGORY Flavonoids / Related Products
Ordering Information
Product Numbers: Format: Size: Unit Price: Quantity: Add To Cart
ALX-385-031-G005   5 g 30.00 USD Add To Cart
ALX-385-031-G025   25 g 90.00 USD Add To Cart
Product Specification
FORMULA: C28H32O15
MW: 608.5
CAS NUMBER: 520-27-4
MERCK INDEX: 14: 3297
SOURCE/HOST: Isolated from Citrus aurantium L. and Citrus reticulate Blanca.
PURITY: ≥90% (HPLC)
APPEARANCE: Light yellow to brown yellow powder.
SOLUBILITY: Soluble in DMSO (50mg/ml).
SHIPPING: AMBIENT
LONG TERM STORAGE: +4°C
IDENTITY: Determined by IR.

Product Description

Flavonoid glycoside. Main component in citrus fruits. Phlebotropic drug used to control internal symptoms of hemorrhoids and in the treatment of venous diseases. Prolongs the vasoconstrictor effect of noradrenaline on the vein wall. Reduces venous hyperpressure. Reduces capillary hyperpermeability and the expression of endothelial adhesion molecules (ICAM1, VCAM1). Effectively inhibits the P-glycoprotein (Pgp)-mediated efflux in cells. Anti-inflammatory. Inhibits lipopolysaccharide (LPS)-induced endothelial cytotoxicity.

Product Specific Literature References
Clinical trial of oral diosmin (Daflon) in the treatment of hemorrhoids: W. Thanapongsathorn & T. Vajrabukka; Dis. Colon Rectum 35, 1085 (1992) Abstract
Amine uptake inhibition by diosmin and diosmetin in human neuronal and neuroendocrine cell lines: E. Sher, et al.; Pharmacol. Res. 26, 395 (1992) Abstract
Antioxidant activity of micronized diosmin on oxygen species from stimulated human neutrophils: B. Cypriani, et al.; Biochem. Pharmacol. 45, 1531 (1993) Abstract
Diosmin-induced increase in sensitivity to Ca2+ of the smooth muscle contractile apparatus in the rat isolated femoral vein: J.P. Savineau & R. Marthan; Br. J. Pharmacol. 111, 978 (1994) Abstract; Full Text
Venous elasticity after treatment with Daflon 500 mg: V. Ibegbuna, et al.; Angiology 48, 45 (1997) Abstract
Chemopreventive effects of diosmin and hesperidin on N-butyl-N-(4-hydroxybutyl)nitrosamine-induced urinary-bladder carcinogenesis in male ICR mice: M. Yang, et al.; Int. J. Cancer 73, 719 (1997) Abstract
Diosmin and diosmetin are agonists of the aryl hydrocarbon receptor that differentially affect cytochrome P450 1A1 activity: H.P. Ciolino, et al.; Cancer Res. 58, 2754 (1998) Abstract; Full Text
Modulation by phytochemicals of cytochrome P450-linked enzyme activity: R.W. Teel & H. Huynh; Cancer Lett. 133, 135 (1998) Abstract
Inhibition of lipopolysaccharide (LPS)-induced endothelial cytotoxicity by diosmin: M.F. Melzig & R. Loose; Pharmazie 54, 298 (1999) Abstract
Anti-inflammatory activity of diosmin and hesperidin in rat colitis induced by TNBS: M.E. Crespo, et al.; Planta Med. 65, 651 (1999) Abstract
Further investigation of the modifying effect of various chemopreventive agents on apoptosis and cell proliferation in human colon cancer cells: Q. Zheng, et al.; J. Cancer Res. Clin. Oncol. 128, 539 (2002) Abstract
The effect of diosmin hesperidin on intestinal ischaemia--reperfusion injury: M. Pehlivan, et al.; Acta Chir. Belg. 104, 715 (2004) Abstract
Treatment of metastatic melanoma B16F10 by the flavonoids tangeretin, rutin, and diosmin: C. Martinez Conesa, et al.; J. Agric. Food Chem. 53, 6791 (2005) Abstract
 
 
ALX-270-097 Revised 07-Sep-06
Ebselen
Add to Clipboard
SYNONYMS 2-Phenyl-1,2-benzisoselenazol-3-(2H)-one
PRODUCT LINE Oxidative Stress
PRODUCT CATEGORY Peroxynitrite / Scavengers / Detection
Ordering Information
Product Numbers: Format: Size: Unit Price: Quantity: Add To Cart
ALX-270-097-M001   1 mg 12.00 USD Add To Cart
ALX-270-097-M005   5 mg 20.00 USD Add To Cart
ALX-270-097-M025   25 mg 60.00 USD Add To Cart
Product Specification
FORMULA: C13H9NOSe
MW: 274.2
CAS NUMBER: 60940-34-3
PURITY: ≥98% (NMR)
APPEARANCE: White to off-white crystalline solid.
SOLUBILITY: Soluble in DMSO.
SHIPPING: AMBIENT
LONG TERM STORAGE: -20°C
HANDLING: Protect from light.

Product Description
Selenium-based inhibitor of protein kinase C, NADPH, 5-lipoxygenase, cyclooxygenase (COX) and NADPH oxidase. Anti-inflammatory antioxidant. Mimics glutathione peroxidase. Inhibits oxidative modifications of low density lipoproteins (LDL).
Product Specific Literature References
A novel biologically active seleno-organic compound--III. Effects of PZ 51 (Ebselen) on glutathione peroxidase and secretory activities of mouse macrophages: M.J. Parnham & S. Kindt; Biochem. Pharmacol. 33, 3247 (1984) Abstract
Seleno-organic compounds and the therapy of hydroperoxide-linked pathological conditions: M.J. Parnham & E. Graf; Biochem. Pharmacol. 36, 3095 (1987) Abstract
Kinetic mechanism and substrate specificity of glutathione peroxidase activity of ebselen (PZ51): M. Maiorino, et al.; Biochem. Pharmacol. 37, 2267 (1988) Abstract
Studies on the anti-inflammatory activity of ebselen. Ebselen interferes with granulocyte oxidative burst by dual inhibition of NADPH oxidase and protein kinase C?: I.A. Cotgreave, et al.; Biochem. Pharmacol. 38, 649 (1989) Abstract
T. Nikawa, et al.; Biochem. Pharmacol. 47, 1007 (1994) Abstract
Effects of ebselen and probucol on oxidative modifications of lipid and protein of low density lipoprotein induced by free radicals: N. Noguchi, et al.; Biochim. Biophys. Acta 1213, 176 (1994) Abstract
Strong inhibition of mammalian lipoxygenases by the antiinflammatory seleno-organic compound ebselen in the absence of glutathione: C. Schewe, et al.; Biochem. Pharmacol. 48, 65 (1994) Abstract
Ebselen: a glutathione peroxidase mimic: H. Sies; Meth. Enzymol. 234, 476 (1994) Abstract
Molecular actions of ebselen-an antiinflammatory antioxidant: T. Schewe; Gen. Pharmacol. 26, 1153 (1995) Abstract
Ebselen: H. Sies; Meth. Enzymol. 252, 341 (1995) Abstract
Ebselen as a glutathione peroxidase mimic and as a scavenger of peroxynitrite: H. Sies & H. Masumoto; Adv. Pharmacol. 38, 229 (1997) Abstract
Free radical generation by selenium compounds and their prooxidant toxicity: J.E. Spallholz; Biomed. Environ. Sci. 10, 260 (1997) Abstract
Protection against peroxynitrite by selenoproteins: H. Sies, et al.; Z. Naturforsch. [C] 53, 228 (1998) Abstract
Ebselen protects mice against T cell-dependent, TNF-mediated apoptotic liver injury: G. Tiegs, et al.; J. Pharmacol. Exp. Ther. 287, 1098 (1998) Abstract; Full Text
 
 
ALX-201-240 Revised 16-Sep-08
Elafin (human) (recombinant)
Add to Clipboard
SYNONYMS ESI (human) (recombinant)
Elastase-specific Inhibitor (human) (recombinant)
SKALP (human) (recombinant)
Skin-derived Antileukoproteinase (human) (recombinant)
Protease Inhibitor WAP3 (human) (recombinant)
PRODUCT LINE Immunology
PRODUCT CATEGORY Antimicrobial Peptides & Proteins / Related Products
Ordering Information
Product Numbers: Format: Size: Unit Price: Quantity: Add To Cart
ALX-201-240-C100   100 µg 275.00 USD Add To Cart
Product Specification
MW: ~5.9kDa
SOURCE/HOST: Produced in yeast.
PURITY: ≥90% (HPLC, SDS-PAGE, MS)
APPEARANCE: White to faint yellow powder.
FORMULATION: Lyophilized.
RECONSTITUTION: Reconstitute in sterile distilled water. Further dilutions should be made in aqueous buffers, pH 4.0-8.0.
BIOLOGICAL ACTIVITY: Inhibits human leukocyte elastase (Ki=0.17nM) and human proteinase 3 (Ki=0.42nM) .
SPECIFIC ACTIVITY: Inhibition of human leukocyte elastase: ≥90%
SHIPPING: SHIPPED ON BLUE ICE
LONG TERM STORAGE: -20°C
HANDLING: After opening, prepare aliquots and store at -20°C. Avoid freeze/thaw cycles.
HAZARD: HARMFUL.
Product Description
Belongs to the chelonianin family of protease inhibitors and is involved in the physiological control of neutrophil serine proteinases, where it targets NE and proteinase 3. Shows antiprotease, antibacterial and antiinflammatory activity and primes innate immunity.
Product Specific Literature References
[1] Elafin: an elastase-specific inhibitor of human skin. Purification, characterization, and complete amino acid sequence: O. Wiedow, et al.; J. Biol. Chem. 265, 14791 (1990) Abstract; Full Text
[2] Skin-derived antileucoproteases (SKALPs): characterization of two new elastase inhibitors from psoriatic epidermis: J. Schalkwijk, et al.; Br. J. Dermatol. 122, 631 (1990) Abstract
[3] Purification and characterization of elastase-specific inhibitor. Sequence homology with mucus proteinase inhibitor: J.M. Sallenave and A.P. Ryle; Biol. Chem. Hoppe Seyler 372, 13 (1991) Abstract
[4] Primary structure of the human elafin precursor preproelafin deduced from the nucleotide sequence of its gene and the presence of unique repetitive sequences in the prosegment: Saheki, et al.; Biochem. Biophys. Res. Commun. 185, 240 (1992) Abstract
[5] Kinetics of the inhibition of human leukocyte elastase by elafin, a 6-kilodalton elastase-specific inhibitor from human skin: Q.L. Ying and S.R. Simon; Biochemistry 32, 1866 (1993) Abstract
[6] SKALP/elafin: an elastase inhibitor from cultured human keratinocytes. Purification, cDNA sequence, and evidence for transglutaminase cross-linking: H.O. Molhuizen, et al.; J. Biol. Chem. 268, 12028 (1993) Abstract
[7] Characterization and gene sequence of the precursor of elafin, an elastase-specific inhibitor in bronchial secretions: J.M. Sallenave and A. Silva; Am. J. Respir. Cell. Mol. Biol. 8, 439 (1993) Abstract
[8] Kinetics of the inhibition of human leukocyte elastase by elafin, a 6-kilodalton elastase-specific inhibitor from human skin: Q.L. Ying and S.R. Simon; Biochemistry 32, 1866 (1993) Abstract
[9] Elastase inhibitor elafin is a new type of proteinase inhibitor which has a transglutaminase-mediated anchoring sequence termed "cementoin": K. Nara, et al.; J. Biochem. (Tokyo) 115, 441 (1994) Abstract
[10] Accelerated evolution in inhibitor domains of porcine elafin family members: I. Tamechika, et al.; J. Biol. Chem. 271, 7012 (1996) Abstract; Full Text
[11] Identification and sequence analysis of two new members of the SKALP/elafin and SPAI-2 gene family. Biochemical properties of the transglutaminase substrate motif and suggestions for a new nomenclature: P.L. Zeeuwen, et al.; J. Biol. Chem. 272, 20471 (1997) Abstract; Full Text
[12] The trappin gene family: proteins defined by an N-terminal transglutaminase substrate domain and a C-terminal four-disulphide core: J. Schalkwijk, et al.; Biochem. J. 340, 569 (1999) Abstract; Full Text
[13] The role of secretory leukocyte proteinase inhibitor and elafin (elastase-specific inhibitor/skin-derived antileukoprotease) as alarm antiproteinases in inflammatory lung disease: J.M. Sallenave; Respir. Res. 1, 87 (2000) Abstract
[14] Kinetics of the inhibition of proteinase 3 by elafin: Q.L. Ying and S.R. Simon; Am. J. Respir. Cell Mol. Biol. 24, 83 (2001) Abstract
[15] Trappin ovine molecule (TOM), the ovine ortholog of elafin, is an acute phase reactant in the lung: T.I. Brown, et al.; Physiol. Genomics 19, 11 (2004) Abstract; Full Text
[16] Elafin and Its Precursor Trappin-2 Still Inhibit Neutrophil Serine Proteinases when They Are Covalently Bound to Extracellular Matrix Proteins by Tissue Transglutaminase: N. Guyot, et al.; Biochemistry 44, 15610 (2005) Abstract
[17] SLPI and elafin: one glove, many fingers: S.E. Williams, et al.; Clin. Sci. (Lond) 110, 21 (2006) Abstract
 
 
ALX-350-057 Revised 20-Feb-08
Emodin
Add to Clipboard
SYNONYMS 6-Methyl-1,3,8-trihydroxyanthraquinone
PRODUCT LINE Natural Products / Antibiotics
PRODUCT CATEGORY Natural Products - Protein Kinase Inhibitors
Ordering Information
Product Numbers: Format: Size: Unit Price: Quantity: Add To Cart
ALX-350-057-M025   25 mg 45.00 USD Add To Cart
Product Specification
FORMULA: C15H10O5
MW: 270.2
CAS NUMBER: 518-82-1
MERCK INDEX: 14: 3561
RTECS: CB7920600
SOURCE/HOST: Isolated from Frangula bark.
PURITY: ≥96% (HPLC)
APPEARANCE: Orange to red solid.
SOLUBILITY: Soluble in DMSO, 100% ethanol or 1N dilute aqueous ammonia; insoluble in water.
SHIPPING: AMBIENT
LONG TERM STORAGE: +4°C
HAZARD: IRRITANT.

Product Description
Inhibitor of p56lck tyrosine kinase. Has mutagenic and genotoxic effects, mainly in bacterial systems. Anticancer agent. Exhibits anti-proliferative effects in various cancer cell lines by efficient induction of apoptosis. Has inhibitory effects on angiogenic and metastasis regulatory processes. Anti-inflammatory compound. Suppresses NF-κB activation. 
Product Specific Literature References
Emodin, a protein tyrosine kinase inhibitor from Polygonum cuspidatum: H. Jayasuriya, et al.; J. Nat. Prod. 55, 696 (1992) Abstract
Selective inhibition of the growth of ras-transformed human bronchial epithelial cells by emodin, a protein-tyrosine kinase inhibitor: T.C.K. Chan, et al.; BBRC 193, 1152 (1993) Abstract
Molecular mechanism of emodin action: transition from laxative ingredient to an antitumor agent: G. Srinivas, et al.; Med. Res. Rev. 27, 591 (2007), (Review) Abstract
 
 
ALX-270-263 Revised 03-Apr-08
(-)-Epigallocatechin gallate
Add to Clipboard
SYNONYMS EGCG
(2R,3R)-2-(3,4,5-Trihydroxyphenyl)-3,4-dihydro-1[2H]-benzopyran-3,5,7-triol 3-(3,4,5-trihydroxybenzoate)
PRODUCT LINE Natural Products / Antibiotics
PRODUCT CATEGORY Natural Products - Antioxidants
Ordering Information
Product Numbers: Format: Size: Unit Price: Quantity: Add To Cart
ALX-270-263-M010   10 mg 20.00 USD Add To Cart
ALX-270-263-M050   50 mg 60.00 USD Add To Cart
Product Specification
FORMULA: C22H18O11
MW: 458.4
CAS NUMBER: 989-51-5
MERCK INDEX: 14: 3526
SOURCE/HOST: Isolated from green tea.
PURITY: ≥98% (HPLC)
APPEARANCE: Off-white to yellow powder.
SOLUBILITY: Soluble in 100% ethanol, dimethyl formamide or DMSO; slightly soluble in water.
SHIPPING: AMBIENT
LONG TERM STORAGE: +4°C
USE/STABILITY: Stock solutions in DMSO are stable for up to 3 months when stored at -20°C.
HANDLING: After reconstitution, prepare aliquots and store at -20°C. Keep under inert gas. Protect from light.

Product Description
Antitumor reagent. Antioxidant. Protects cells from lipid peroxidation and DNA damage induced by reactive free radicals. Inhibits inducible nitric oxide synthase (iNOS; NOS II). Chemopreventive anticancer agent. Induces apoptosis in human cancer cell lines. Inhibits MAP kinase mediated signalling pathways. Inhibits angiogenesis. Inhibits telomerase and DNA methyltransferase. Anti-inflammatory agent.
Product Specific Literature References
Inhibitory effect of topical application of a green tea polyphenol fraction on tumor initiation and promotion in mouse skin: M.T. Huang, et al.; Carcinogenesis 13, 947 (1992) Abstract
Inhibition of 12-O-tetradecanoylphorbol-13-acetate and other skin tumor-promoter-caused induction of epidermal interleukin-1 alpha mRNA and protein expression in SENCAR mice by green tea polyphenols: S.K. Katiyar, et al.; J. Invest. Dermatol. 105, 394 (1995) Abstract
Growth inhibition and regression of human prostate and breast tumors in athymic mice by tea epigallocatechin gallate: S. Liao, et al.; Cancer Lett. 96, 239 (1995) Abstract
Inhibition of N-methyl-N'-nitro-N-nitrosoguanidine-induced carcinogenesis by (-)-epigallocatechin gallate in the rat glandular stomach: T. Yamane, et al.; Cancer Res. 55, 2081 (1995) Abstract
(-)-Epigallocatechin gallate, a polyphenolic tea antioxidant, inhibits peroxynitrite-mediated formation of 8-oxodeoxyguanosine and 3-nitrotyrosine: E.S. Fiala, et al.; Experientia 52, 922 (1996) Abstract
Green tea constituent epigallocatechin-3-gallate and induction of apoptosis and cell cycle arrest in human carcinoma cells: N. Ahmad, et al.; J. Natl. Cancer Inst. 89, 1881 (1997) Abstract
Inhibition of inducible nitric oxide synthase gene expression and enzyme activity by epigallocatechin gallate, a natural product from green tea: M.M. Chan, et al.; Biochem. Pharmacol. 54, 1281 (1997) Abstract
(-)-Epigallocatechin-3-gallate blocks the induction of nitric oxide synthase by down-regulating lipopolysaccharide-induced activity of transcription factor nuclear factor-kappaB: Y.L. Lin & J.K. Lin; Mol. Pharmacol. 52, 465 (1997) Abstract
Telomerase inhibition, telomere shortening, and senescence of cancer cells by tea catechins: I. Naasani, et al.; BBRC 249, 391 (1998) Abstract
Epigallocatechin suppression of proliferation of vascular smooth muscle cells: correlation with c-jun and JNK: L.H. Lu, et al.; Br. J. Pharmacol. 124, 1227 (1998) Abstract
ESR study on the structure-antioxidant activity relationship of tea catechins and their epimers: Q. Guo, et al.; Biochim. Biophys. Acta 1427, 13 (1999) Abstract
Pharmacokinetics of the green tea derivative, EGCG, by the topical route of administration in mouse and human skin: K. Dvorakova, et al.; Cancer Chemother. Pharmacol. 43, 331 (1999) Abstract
Polyphenolic antioxidant (-)-epigallocatechin-3-gallate from green tea reduces UVB-induced inflammatory responses and infiltration of leukocytes in human skin: S.K. Katiyar, et al.; Photochem. Photobiol. 69, 148 (1999) Abstract
Antioxidant chemistry of green tea catechins. Identification of products of the reaction of (-)-epigallocatechin gallate with peroxyl radicals: S. Valcic, et al.; Chem. Res. Toxicol. 12, 382 (1999) Abstract
Antimutagenic and anticarcinogenic activity of tea polyphenols: Y. Kuroda & Y. Hara; Mutat. Res. 436, 69 (1999) Abstract
Inhibitory effect of green and black tea on tumor growth: A.H. Conney, et al.; Proc. Soc. Exp. Biol. Med. 220, 229 (1999) Abstract
Green tea epigallocatechin gallate: a natural inhibitor of fatty-acid synthase: X. Wang & W. Tian; BBRC 288, 1200 (2001) Abstract
Epigallocatechin gallate, a constituent of green tea, represses hepatic glucose production: M.E. Waltner-Law, et al.; J. Biol. Chem. 277, 34933 (2002) Abstract; Full Text
The specificities of protein kinase inhibitors: an update:: J. Bain, et al.; Biochem. J. 371, 199 (2003) Abstract; Full Text
Selective inhibition of ADAMTS-1, -4 and -5 by catechin gallate esters: M.N. Vankemmelbeke, et al.; Eur. J. Biochem. 270, 2394 (2003) Abstract
Epigallocatechin-3-gallate, constituent of green tea, suppresses the LPS-induced phenotypic and functional maturation of murine dendritic cells through inhibition of mitogen-activated protein kinases and NF-kappaB: S.C. Ahn, et al.; BBRC 313, 148 (2004) Abstract
Epigallocatechin-3-gallate inhibits epidermal growth factor receptor signaling pathway. Evidence for direct inhibition of ERK1/2 and AKT kinases: J.F. Sah, et al.; J. Biol. Chem. 279, 12755 (2004) Abstract
Inhibition of c-Jun NH2-terminal kinase activity improves ischemia/reperfusion injury in rat lungs: M. Ishii, et al.; J. Immunol. 172, 2569 (2004) Abstract
A constituent of green tea, epigallocatechin-3-gallate, activates endothelial nitric oxide synthase by a phosphatidylinositol-3-OH-kinase-, cAMP-dependent protein kinase-, and Akt-dependent pathway and leads to endothelial-dependent vasorelaxation: M. Lorenz, et al.; J. Biol. Chem. 279, 6190 (2004) Abstract; Full Text
Green tea polyphenols prevent toxin-induced hepatotoxicity in mice by down-regulating inducible nitric oxide-derived prooxidants: J.H. Chen, et al.; Am. J. Clin. Nutr. 80, 742 (2004) Abstract; Full Text
Neuroprotective effects of (-)-epigallocatechin gallate following hypoxia-ischemia-induced brain damage: novel mechanisms of action: B.A. Sutherland, et al.; FASEB J. 19, 258 (2005) Abstract; Full Text
Tea flavanols inhibit angiotensin-converting enzyme activity and increase nitric oxide production in human endothelial cells: I.A. Persson, et al.; J. Pharm. Pharmacol. 58, 1139 (2006) Abstract
General Literature References
Anticarcinogenic effects of (-)-epigallocatechin gallate: H. Fujiki, et al.; Prev. Med. 21, 503 (1992), (Review) Abstract
Absorption, metabolism and antioxidative effects of tea catechin in humans: T. Miyazawa; Biofactors 13, 55 (2000), (Review) Abstract
Inhibition of tumour invasion and angiogenesis by epigallocatechin gallate (EGCG), a major component of green tea: Y.D. Jung and L.M. Ellis; Int. J. Exp. Pathol. 82, 309 (2001), (Review) Abstract
Anti-invasive effects of green tea polyphenol epigallocatechin-3-gallate (EGCG), a natural inhibitor of metallo and serine proteases: R. Benelli, et al.; Biol. Chem. 383, 101 (2002), (Review) Abstract
 
 
ALX-350-254 Revised 10-Mar-08
Epoxomicin
Add to Clipboard
PRODUCT LINE Natural Products / Antibiotics
PRODUCT CATEGORY Antibiotics - Proteasome / Ubiquitin Modulators
Ordering Information
Product Numbers: Format: Size: Unit Price: Quantity: Add To Cart
ALX-350-254-C050   50 µg 132.00 USD Add To Cart
Product Specification
FORMULA: C28H50N4O7
MW: 554.7
CAS NUMBER: 134381-21-8
MERCK INDEX: 14: 3630
SOURCE/HOST: Synthetic.
PURITY: ≥95% (HPLC)
APPEARANCE: White to off-white solid.
SOLUBILITY: Soluble in DMSO (15mg/ml); insoluble in water.
ACTIVITY: kobs/[I] = 25’000M-1s-1 versus 20S proteasome.
SHIPPING: AMBIENT
LONG TERM STORAGE: -20°C
HANDLING: Avoid freeze/thaw cycles. Protect from light.
IDENTITY: Identity determined by 1H-NMR.

Product Description
Cell permeable, potent and selective proteasome inhibitor originally isolated from Actinomycetes strain based on its potent in vivo antitumor activity. More potent inhibitor of the chymotrypsin-like activity of the proteasome than lactacystin. Effectively inhibits NF-κB activation in vitro and potently blocks inflammation in vivo in the mouse ear edema assay.
Product Specific Literature References
Epoxomicin, a new antitumor agent of microbial origin: M. Hanada, et al.; J. Antibiot. (Tokyo) 45, 1746 (1992) Abstract
Proteasome inhibition by the natural products epoxomicin and dihydroeponemycin: insights into specificity and potency: K.B. Kim, et al.; Bioorg. Med. Chem. Lett. 9, 3335 (1999) Abstract
Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity: L. Meng, et al.; PNAS 96, 10403 (1999) Abstract
Total synthesis of the potent proteasome inhibitor epoxomicin: a useful tool for understanding proteasome biology: N. Sin, et al.; Bioorg. Med. Chem. Lett. 9, 2283 (1999) Abstract
The selective proteasome inhibitors lactacystin and epoxomicin can be used to either up- or down-regulate antigen presentation at nontoxic doses: K. Schwarz, et al.; J. Immunol. 164, 6147 (2000) Abstract
Establishment and some characteristics of epoxomicin (a proteasome inhibitor) resistant variants of the human squamous cell carcinoma cell line, A431: K. Ohkawa, et al.; Int. J. Oncol. 24, 425 (2004) Abstract
<